ANGLE Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ANGLE de 42.4% y 46.6% respectivamente, mientras que el BPA crecerá en un 42.4% al año.

Información clave

42.4%

Tasa de crecimiento de los beneficios

42.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	21.5%
Tasa de crecimiento de los ingresos	46.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	30 Jan 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

AIM:AGL - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	36	-6	N/A	-6	2
12/31/2025	17	-14	N/A	-11	2
12/31/2024	8	-15	N/A	-12	3
12/31/2023	2	-19	N/A	-15	2
6/30/2023	2	-22	-16	-15	N/A
3/31/2023	1	-22	-17	-16	N/A
12/31/2022	1	-22	-18	-16	N/A
9/30/2022	1	-19	-19	-17	N/A
6/30/2022	1	-17	-19	-18	N/A
3/31/2022	1	-16	-18	-16	N/A
12/31/2021	1	-15	-16	-14	N/A
9/30/2021	1	-15	-13	-12	N/A
6/30/2021	1	-16	-11	-10	N/A
3/31/2021	1	-14	-10	-9	N/A
12/31/2020	1	-12	-8	-8	N/A
6/30/2020	1	-10	-14	-15	N/A
3/31/2020	1	-11	-14	-14	N/A
12/31/2019	1	-11	-13	-13	N/A
10/31/2019	1	-10	-11	-9	N/A
7/31/2019	1	-9	-10	-8	N/A
4/30/2019	1	-9	-9	-7	N/A
1/31/2019	1	-9	-9	-7	N/A
10/31/2018	1	-8	-9	-7	N/A
7/31/2018	1	-8	-9	-7	N/A
4/30/2018	1	-8	-9	-7	N/A
10/31/2017	0	-7	-9	-8	N/A
7/31/2017	0	-7	-8	-8	N/A
4/30/2017	0	-7	N/A	-7	N/A
10/31/2016	1	-5	N/A	-5	N/A
7/31/2016	0	-5	N/A	-5	N/A
4/30/2016	0	-5	N/A	-4	N/A
1/31/2016	0	-5	N/A	-4	N/A
10/31/2015	N/A	-4	N/A	-4	N/A
7/31/2015	N/A	-4	N/A	-4	N/A
4/30/2015	N/A	-4	N/A	-3	N/A
10/31/2014	-1	-3	N/A	-3	N/A
7/31/2014	0	-3	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A
1/31/2014	2	-1	N/A	-2	N/A
10/31/2013	2	-1	N/A	-1	N/A
7/31/2013	2	-1	N/A	-1	N/A
4/30/2013	1	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AGL siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que AGL siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que AGL siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (46.6% al año) de AGL crezcan más rápidamente que los del mercado UK (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (46.6% al año) de AGL crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AGL se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ANGLE Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

ANGLE plc Provides Earnings Guidance for the Year 2023

Price target decreased by 35% to UK£0.94

Price target increased to UK£2.16

Recent updates

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate

Full year 2020 earnings released: UK£0.065 loss per share (vs UK£0.057 loss in FY 2019)

ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study

Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System

What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?

Angle plc Announces Results of New Study Undertaken in Non-Small Cell Lung Cancer

New 90-day high: UK£0.80

ANGLE plc Announces Publication of New Data Demonstrating the Performance of its Parsortix® System in a Head-to-Head Comparison with a Antibody-Based CTC System

New 90-day high: UK£0.54

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

New 90-day low: UK£0.44